MedTrace Logo

Efficacy Study of Vaginal Mifepristone to Treat Uterine Fibroids

NCT00881140 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2012-12-19

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effect of daily dosage of vaginally mifepristone on reduction of uterine fibroids size and the symptoms associated with uterine fibroids.

Conditions

  • Uterine Fibroid
  • Vaginal Bleeding.

Interventions

DRUG

mifepristone vaginal tablets

Daily use of 10 mg administrated per vagina for 3 months

Sponsors & Collaborators

  • BioPro Medical Ltd

    lead INDUSTRY

Principal Investigators

  • Daniel Seidman, Prof' · unaffiliation

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
30 Years
Max Age
53 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2012-05-31
Completion
2012-07-31

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00881140 on ClinicalTrials.gov